Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
16-Bromoepiandrosterone is a synthetic steroid and chemical analogue of dehydroepiandrosterone (DHEA), developed as an injectable formulation. It was selected for development after demonstrating antiretroviral activity in laboratory tests. Unlike DHEA, it lacks anabolic effects but amplifies immune and metabolic responses. The compound has been investigated for its potential to limit nonproductive inflammation, enhance protective immunity, and improve survival in infections such as HIV, malaria, tuberculosis, hepatitis B and C, cytomegalovirus, polio, influenza virus, and Cryptosporidium parvum. Its mechanism involves inhibition of glucose 6-phosphate dehydrogenase (G6PDH) and modulation of androgen receptor activity; it also affects cell proliferation through complex interactions with cellular receptors[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 16-bromoepiandrosterone.